^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MBS301

    i
    Other names: MBS301, MBS 301
    Associations

    News

    Trials
    Company:
    Beijing Mabworks Biotech
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=34, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    MBS301
    2years
    Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=34, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    MBS301
    over2years
    Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=34, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: May 2020 --> Aug 2022
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    MBS301